Barbara Gayle Duncan's Net Worth
$6.5 Million
Who is Barbara Gayle Duncan?
Barbara Gayle Duncan has an estimated net worth of $6.5 Million. This is based on reported shares across multiple companies, which include IMMUNOMEDICS INC, Innoviva, Inc., Atea Pharmaceuticals, Inc., INTERCEPT PHARMACEUTICALS INC, Fusion Pharmaceuticals Inc., Jounce Therapeutics, Inc., Ovid Therapeutics Inc., Adaptimmune Therapeutics PLC, Aevi Genomic Medicine, Inc., HALOZYME THERAPEUTICS, INC., and DOV PHARMACEUTICAL INC.
SEC CIK
Barbara Gayle Duncan's CIK is 0001353128
Past Insider Trading and Trends
2013 was Barbara Gayle Duncan's most active year for acquiring shares with 13 total transactions. Barbara Gayle Duncan's most active month to acquire stocks was the month of May. 2015 was Barbara Gayle Duncan's most active year for disposing of shares, totalling 25 transactions. Barbara Gayle Duncan's most active month to dispose stocks was the month of December. 2006 saw Barbara Gayle Duncan paying a total of $742,000.00 for 350,000 shares, this is the most they've acquired in one year. In 2013 Barbara Gayle Duncan cashed out on 231,762 shares for a total of $4,159,853.72, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
IMMUNOMEDICS INC No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -49.24K |
—
|
—
|
0
|
Oct 23
| |||
Form 4
| +6.74% | 2.5K |
$16.96 | $42,400.00 | 39.58K |
Sep 14
| |||
Form 4
| +117.12% | 20K |
$16.96 | $339,200.00 | 37.08K |
Aug 17
| |||
Form 4
|
∞
| 17.08K |
$12.93 | $220,805.61 | 17.08K |
Aug 12
| |||
Form 4
| +38.46% | 3.72K |
—
|
—
| 13.38K |
Jun 18
| |||
Form 4
|
∞
| 9.67K |
—
|
—
| 9.67K |
Jun 7
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 5
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Innoviva, Inc. (INVA) Snapshot price: $15.605
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +61.17% | 19.86K |
—
|
—
| 52.32K |
Apr 20
| |||
Form 4
|
∞
| 32.46K |
—
|
—
| 32.46K |
Nov 18
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Atea Pharmaceuticals, Inc. (AVIR) Snapshot price: $4.3
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 21
| |||
Form 4
|
∞
| 33.15K |
—
|
—
| 33.15K |
Jun 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 17
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 18
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 29
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
INTERCEPT PHARMACEUTICALS INC (ICPT) No price found
Chief Accounting Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -0.48% | -147.00 |
$163.20 | -$23,990.36 | 30.66K |
Oct 3
| |||
Form 4
| -0.47% | -146.00 |
$145.11 | -$21,185.94 | 30.81K |
Jul 5
| |||
Form 4
| -0.46% | -144.00 |
$130.76 | -$18,829.44 | 30.95K |
Apr 4
| |||
Form 4
| +24.91% | 6.2K |
—
|
—
| 31.09K |
Feb 10
| |||
Form 4
| +3.45% | 830 |
$145.90 | -$68,282.93 | 24.89K |
Jan 1 - Jan 4
| |||
Form 4
| +28.21% | 5.29K |
$85.92 | -$171,978.12 | 24.06K |
Scheduled
|
Oct 1 - Oct 2
| ||
Form 4
| +7.10% | 1.25K |
$236.26 | -$12,521.82 | 18.77K |
Jul 1 - Jul 2
| |||
Form 4
|
—
|
0
|
$125.39 | -$233,433.00 | 17.52K |
Scheduled
|
Jul 1
| ||
Form 4
| +7.74% | 1.26K |
$277.70 | -$10,830.32 | 17.52K |
Apr 1 - Apr 2
| |||
Form 4
| -5.79% | -1.00K |
$289.82 | -$289,817.25 | 16.26K |
Mar 27
| |||
Form 4
| -0.81% | -141.00 |
$176.49 | -$24,884.48 | 17.26K |
Jan 5
| |||
Form 4
| +8.06% | 1.3K |
$94.15 | -$156,400.05 | 17.41K |
Scheduled
|
Jan 1 - Jan 2
| ||
Form 4
| +8.77% | 1.3K |
$132.51 | -$233,118.96 | 16.11K |
Scheduled
|
Oct 1
| ||
Form 4
| +9.61% | 1.3K |
—
|
—
| 14.81K |
Jul 1
| |||
Form 4
| +12.53% | 1.5K |
$150.25 | -$297,155.00 | 13.51K |
Scheduled
|
Apr 11 - Apr 14
| ||
Form 4
| +12.12% | 1.3K |
—
|
—
| 12.01K |
Apr 1
| |||
Form 4
|
—
|
0
|
$145.54 | -$1,278,477.48 | 10.71K |
Scheduled
|
Jan 15
| ||
Form 4
| +13.79% | 1.3K |
—
|
—
| 10.71K |
Jan 1
| |||
Form 4
| +16.00% | 1.3K |
—
|
—
| 9.41K |
Oct 1
| |||
Form 4
|
—
|
0
|
$27.61 | -$889,282.50 | 8.11K |
Scheduled
|
Jul 8
| ||
Form 4
| +19.05% | 1.3K |
—
|
—
| 8.11K |
Jul 1
| |||
Form 4
|
—
|
0
|
$22.07 | -$1,257,963.15 | 63.57K |
Scheduled
|
Jun 19
| ||
Form 4
|
—
|
0
|
$21.59 | -$160,816.69 | 6.81K |
Scheduled
|
May 23 - May 28
| ||
Form 4
|
—
|
0
|
$22.57 | -$672,969.37 | 6.81K |
Scheduled
|
May 20
| ||
Form 4
| +78.66% | 3K |
—
|
—
| 6.81K |
May 7
| |||
Form 4
|
∞
| 3.81K |
$34.57 | -$92,509.32 | 3.81K |
Apr 9
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Nov 16
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Fusion Pharmaceuticals Inc. (FUSN) Snapshot price: $11.82
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 4
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 4
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 30
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||